Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.9923
+0.0461 (4.87%)
May 8, 2025, 4:00 PM - Market closed
Coherus BioSciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 266.96 | 257.24 | 211.04 | 326.55 | 475.82 | Upgrade
|
| Revenue | 266.96 | 257.24 | 211.04 | 326.55 | 475.82 | Upgrade
|
| Revenue Growth (YoY) | 3.78% | 21.89% | -35.37% | -31.37% | 33.63% | Upgrade
|
| Cost of Revenue | 117.55 | 158.99 | 70.08 | 57.59 | 37.67 | Upgrade
|
| Gross Profit | 149.41 | 98.25 | 140.96 | 268.96 | 438.16 | Upgrade
|
| Selling, General & Admin | 150.44 | 185.62 | 198.48 | 169.71 | 139.08 | Upgrade
|
| Research & Development | 93.34 | 105.84 | 199.36 | 363.11 | 142.76 | Upgrade
|
| Operating Expenses | 243.77 | 291.45 | 397.84 | 532.82 | 281.84 | Upgrade
|
| Operating Income | -94.37 | -193.2 | -256.88 | -263.86 | 156.32 | Upgrade
|
| Interest Expense | -27.16 | -40.54 | -32.47 | -22.96 | -21.17 | Upgrade
|
| Interest & Investment Income | 4.5 | 2.8 | 1.9 | 1.4 | 0.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.13 | 2.67 | 1.92 | -1.68 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -118.15 | -228.27 | -285.53 | -287.1 | 135.71 | Upgrade
|
| Merger & Restructuring Charges | -6.7 | -10 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 176.59 | - | - | - | - | Upgrade
|
| Asset Writedown | -10.6 | - | - | - | - | Upgrade
|
| Other Unusual Items | -12.63 | - | -6.22 | - | - | Upgrade
|
| Pretax Income | 28.51 | -238.27 | -291.75 | -287.1 | 135.71 | Upgrade
|
| Income Tax Expense | - | -0.38 | - | - | 3.46 | Upgrade
|
| Earnings From Continuing Operations | 28.51 | -237.89 | -291.75 | -287.1 | 132.24 | Upgrade
|
| Net Income | 28.51 | -237.89 | -291.75 | -287.1 | 132.24 | Upgrade
|
| Net Income to Common | 28.51 | -237.89 | -291.75 | -287.1 | 132.24 | Upgrade
|
| Net Income Growth | - | - | - | - | 47.21% | Upgrade
|
| Shares Outstanding (Basic) | 115 | 94 | 78 | 75 | 71 | Upgrade
|
| Shares Outstanding (Diluted) | 115 | 94 | 78 | 75 | 83 | Upgrade
|
| Shares Change (YoY) | 21.95% | 21.30% | 2.89% | -9.63% | 14.08% | Upgrade
|
| EPS (Basic) | 0.25 | -2.53 | -3.76 | -3.81 | 1.85 | Upgrade
|
| EPS (Diluted) | 0.25 | -2.53 | -3.76 | -3.81 | 1.62 | Upgrade
|
| EPS Growth | - | - | - | - | 31.99% | Upgrade
|
| Free Cash Flow | -20.44 | -174.88 | -241.12 | -38.72 | 146.91 | Upgrade
|
| Free Cash Flow Per Share | -0.18 | -1.86 | -3.11 | -0.51 | 1.76 | Upgrade
|
| Gross Margin | 55.97% | 38.19% | 66.79% | 82.36% | 92.08% | Upgrade
|
| Operating Margin | -35.35% | -75.10% | -121.72% | -80.80% | 32.85% | Upgrade
|
| Profit Margin | 10.68% | -92.48% | -138.25% | -87.92% | 27.79% | Upgrade
|
| Free Cash Flow Margin | -7.66% | -67.98% | -114.25% | -11.86% | 30.88% | Upgrade
|
| EBITDA | -89.09 | -189.41 | -253.18 | -260.4 | 159.21 | Upgrade
|
| EBITDA Margin | -33.37% | -73.63% | -119.97% | -79.74% | 33.46% | Upgrade
|
| D&A For EBITDA | 5.28 | 3.79 | 3.7 | 3.45 | 2.89 | Upgrade
|
| EBIT | -94.37 | -193.2 | -256.88 | -263.86 | 156.32 | Upgrade
|
| EBIT Margin | -35.35% | -75.10% | -121.72% | -80.80% | 32.85% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 2.55% | Upgrade
|
| Advertising Expenses | 10.9 | 10.9 | 10.5 | - | 3.8 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.